ANI Pharmaceuticals Other Current Liabilities

ANI Pharmaceuticals (ANIP) currently reports a other current liabilities of $180M as of June 2026. That compares with $170M in the prior-year period — up 11.6% year over year. Use the charts on this page to explore ANI Pharmaceuticals's other current liabilities history and peer comparisons.

ANI Pharmaceuticals's other current liabilities increased from $170M to $180M — a 11.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ANI Pharmaceuticals reported $180M in other current liabilities as of June 2026. That compares with $170M in the prior-year period — up 11.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $180M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ANI Pharmaceuticals, and consider following ANIP for alerts when major investors trade the stock.

ANI Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $180M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ANIP with unrelated industries.